These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 34086042)

  • 1. Concordance of DNA Repair Gene Mutations in Paired Primary Prostate Cancer Samples and Metastatic Tissue or Cell-Free DNA.
    Schweizer MT; Sivakumar S; Tukachinsky H; Coleman I; De Sarkar N; Yu EY; Konnick EQ; Nelson PS; Pritchard CC; Montgomery B
    JAMA Oncol; 2021 Jun; 7(9):1-5. PubMed ID: 34086042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.
    Wyatt AW; Annala M; Aggarwal R; Beja K; Feng F; Youngren J; Foye A; Lloyd P; Nykter M; Beer TM; Alumkal JJ; Thomas GV; Reiter RE; Rettig MB; Evans CP; Gao AC; Chi KN; Small EJ; Gleave ME
    J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29206995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.
    Vandekerkhove G; Struss WJ; Annala M; Kallio HML; Khalaf D; Warner EW; Herberts C; Ritch E; Beja K; Loktionova Y; Hurtado-Coll A; Fazli L; So A; Black PC; Nykter M; Tammela T; Chi KN; Gleave ME; Wyatt AW
    Eur Urol; 2019 Apr; 75(4):667-675. PubMed ID: 30638634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Profiling in Daily Clinical Practice: Practicalities in Advanced Cholangiocarcinoma and Other Biliary Tract Cancers.
    Lamarca A; Kapacee Z; Breeze M; Bell C; Belcher D; Staiger H; Taylor C; McNamara MG; Hubner RA; Valle JW
    J Clin Med; 2020 Sep; 9(9):. PubMed ID: 32899345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guardant360 Circulating Tumor DNA Assay Is Concordant with FoundationOne Next-Generation Sequencing in Detecting Actionable Driver Mutations in Anti-EGFR Naive Metastatic Colorectal Cancer.
    Gupta R; Othman T; Chen C; Sandhu J; Ouyang C; Fakih M
    Oncologist; 2020 Mar; 25(3):235-243. PubMed ID: 32162812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
    Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
    Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Commercial Circulating Tumor DNA Test in Metastatic Prostate Cancer.
    Taavitsainen S; Annala M; Ledet E; Beja K; Miller PJ; Moses M; Nykter M; Chi KN; Sartor O; Wyatt AW
    JCO Precis Oncol; 2019; 3():. PubMed ID: 32914020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma.
    Bacon JVW; Annala M; Soleimani M; Lavoie JM; So A; Gleave ME; Fazli L; Wang G; Chi KN; Kollmannsberger CK; Wyatt AW; Nappi L
    Clin Genitourin Cancer; 2020 Aug; 18(4):322-331.e2. PubMed ID: 32046920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms.
    Tukachinsky H; Madison RW; Chung JH; Gjoerup OV; Severson EA; Dennis L; Fendler BJ; Morley S; Zhong L; Graf RP; Ross JS; Alexander BM; Abida W; Chowdhury S; Ryan CJ; Fizazi K; Golsorkhi T; Watkins SP; Simmons A; Loehr A; Venstrom JM; Oxnard GR
    Clin Cancer Res; 2021 Jun; 27(11):3094-3105. PubMed ID: 33558422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis.
    Mayrhofer M; De Laere B; Whitington T; Van Oyen P; Ghysel C; Ampe J; Ost P; Demey W; Hoekx L; Schrijvers D; Brouwers B; Lybaert W; Everaert E; De Maeseneer D; Strijbos M; Bols A; Fransis K; Oeyen S; van Dam PJ; Van den Eynden G; Rutten A; Aly M; Nordström T; Van Laere S; Rantalainen M; Rajan P; Egevad L; Ullén A; Yachnin J; Dirix L; Grönberg H; Lindberg J
    Genome Med; 2018 Nov; 10(1):85. PubMed ID: 30458854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA repair deficiency as circulating biomarker in prostate cancer.
    Catalano M; Generali D; Gatti M; Riboli B; Paganini L; Nesi G; Roviello G
    Front Oncol; 2023; 13():1115241. PubMed ID: 36793600
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Warner E; Herberts C; Fu S; Yip S; Wong A; Wang G; Ritch E; Murtha AJ; Vandekerkhove G; Fonseca NM; Angeles A; Beigi A; Schönlau E; Beja K; Annala M; Khalaf D; Chi KN; Wyatt AW
    Clin Cancer Res; 2021 Mar; 27(6):1650-1662. PubMed ID: 33414135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal profiling of circulating tumour DNA for tracking tumour dynamics in pancreatic cancer.
    Sivapalan L; Thorn GJ; Gadaleta E; Kocher HM; Ross-Adams H; Chelala C
    BMC Cancer; 2022 Apr; 22(1):369. PubMed ID: 35392854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA-Damage-Repair Gene Alterations in Genitourinary Malignancies.
    Dariane C; Timsit MO
    Eur Surg Res; 2022; 63(4):155-164. PubMed ID: 35944490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A generalizable machine learning framework for classifying DNA repair defects using ctDNA exomes.
    Ritch EJ; Herberts C; Warner EW; Ng SWS; Kwan EM; Bacon JVW; Bernales CQ; Schönlau E; Fonseca NM; Giri VN; Maurice-Dror C; Vandekerkhove G; Jones SJM; Chi KN; Wyatt AW
    NPJ Precis Oncol; 2023 Mar; 7(1):27. PubMed ID: 36914848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer.
    Kohli M; Tan W; Zheng T; Wang A; Montesinos C; Wong C; Du P; Jia S; Yadav S; Horvath LG; Mahon KL; Kwan EM; Fettke H; Yu J; Azad AA
    EBioMedicine; 2020 Apr; 54():102728. PubMed ID: 32268276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concordance and Clinical Significance of Genomic Alterations in Progressive Tumor Tissue and Matched Circulating Tumor DNA in Aggressive-variant Prostate Cancer.
    Wang R; Xu Q; Guo H; Yang G; Zhang J; Wang H; Xu T; Guo C; Yuan J; He Y; Zhang X; Fu H; Xu G; Zhao B; Xie J; Zhao T; Huang L; Zhang J; Peng B; Yao X; Yang B
    Cancer Res Commun; 2023 Nov; 3(11):2221-2232. PubMed ID: 37877742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of Plasma Circulating Tumor DNA in Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Modified FOLFIRINOX: Clinical Relevance of DNA Damage Repair Gene Alteration Detection.
    Lim DH; Yoon H; Kim KP; Ryoo BY; Lee SS; Park DH; Song TJ; Hwang DW; Lee JH; Song KB; Kim SC; Hong SM; Hyung J; Yoo C
    Cancer Res Treat; 2023 Oct; 55(4):1313-1320. PubMed ID: 37139665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of
    McFarland TR; Mathew Thomas V; Nussenzveig R; Gebrael G; Sayegh N; Tripathi N; Sahu KK; Goel D; Maughan BL; Sirohi D; Agarwal N; Swami U
    Biomedicines; 2022 Dec; 10(12):. PubMed ID: 36551924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer.
    Chae YK; Davis AA; Jain S; Santa-Maria C; Flaum L; Beaubier N; Platanias LC; Gradishar W; Giles FJ; Cristofanilli M
    Mol Cancer Ther; 2017 Jul; 16(7):1412-1420. PubMed ID: 28446639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.